Synta Pharmaceuticals Corp. (SNTA) Jumps 8.73% on February 17

Equities Staff |

Synta Pharmaceuticals Corp. (SNTA) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 8.73% to $0.24, representing a gain of $0.0191 per share. Some 1.88 million shares traded hands on 1,791 trades, compared with an average daily volume of 1.94 million shares out of a total float of 137.79 million. The stock opened at $0.22 and traded with an intraday range of $0.26 to $0.21.

After today's gains, Synta Pharmaceuticals Corp. reached a market cap of $32.79 million. Synta Pharmaceuticals Corp. has had a trading range between $3.17 and $0.15 over the last year, and it had a 50-day SMA of $0.28 and a 200-day SMA of $1.44.

Synta Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients.

Synta Pharmaceuticals Corp. is based out of Lexington, MA and has some 110 employees. Its CEO is Chen Schor.

For a complete fundamental analysis analysis of Synta Pharmaceuticals Corp., check out’s Stock Valuation Analysis report for SNTA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.